MedTrace Logo

Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment

NCT03359967 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2017-12-02

No results posted yet for this study

Summary

The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronization therapy and/or an implantable cardioverter-defibrillator (ICD; Medtronic Inc., Minneapolis, MN) allowing continuous measurement of intrathoracic impedance.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Entresto tablet

Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)

Sponsors & Collaborators

  • Central Hospital, Izmir

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-12
Primary Completion
2018-06-29
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359967 on ClinicalTrials.gov